Speaker Profile
Ph.D., Chief Scientific Officer, BryoLogyx
Biography
With more than fifteen years of experience in drug discovery and preclinical drug development for small molecules and antibodies, Dr. Duramad oversees BryoLogyx’s preclinical pathway in immuno-oncology. Additionally, Dr. Duramad is Founder of IQ Biosciences where he oversees IQ’s In-vitro Assay Services (Testing, Safety, Toxicology, & Immunology). Previously, Dr. Duramad held positions of increasing responsibility at REGiMMUNE, IGM Biosciences, Neothera Biosciences, and Dynavax Technologies. An immunologist by training, Dr. Duramad has received several awards such as the Schissler Foundation Fellowship in Cancer Research, American Legion Auxiliary Fellowship for Cancer Research, and the Vivian L. Smith Award for Outstanding Immunologist and has been an invited speaker at conferences such as Keystone Symposia, American Society of Hematology, and American Transplant Congress. Dr. Duramad obtained Ph.D. in Immunology & Cancer Biology from the University of Texas, MD Anderson Cancer Center in Houston.
Immunotherapy Showcase:
BryoLogyx
Making Tumors Hot: Tumor-antigen stimulating drugs to enhance the efficacy of cancer immuno-therapeutics.
Expanding The Horizon Of Immuno-Oncology
We will show how we are addressing antigen escape and why we believe our efforts will have a significant impact on increasing immunotherapy response rates and durable responses for cancer patients.
Session Abstract – PMWC 2020 Silicon Valley
The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.
